India Diabetes Care Drugs Market
India Diabetes Care Drugs Market Size, Share & Trends Analysis Report by By Diabetes Type (Type 1 diabetes, Type 2 diabetes, Gestational diabetes, Prediabetes / prevention), By Drug Class (Insulins, Biguanides, Sulfonylureas, Thiazolidinediones (TZDs), DPP-4 inhibitors, SGLT2 inhibitors, Others), By Formulation & Route (Oral tablets, Subcutaneous injections, and Inhalable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), Forecast Period (2026-2035)
Industry Overview
India diabetes care drugs market was valued at $2,983.2 million in 2025 and is projected to reach $6,984.5 million by 2035, growing at a CAGR of 9.0% during the forecast period (2026–2035). The India diabetes care drugs market is witnessing consistent growth, supported by the rising prevalence of diabetes across urban and semi-urban populations. Rapid lifestyle changes, increasing obesity rates, and genetic predisposition have significantly expanded the patient base requiring long-term treatment. Improvements in healthcare access and diagnostic capabilities are enabling earlier identification and sustained management of the disease. Pharmaceutical advancements, including the wider availability of affordable generics and biosimilars, are improving treatment penetration across income groups. Active participation of domestic manufacturers alongside multinational companies is strengthening market competition and product availability. Additionally, growing awareness of diabetes management and supportive government health initiatives continue to reinforce market expansion.
Market Dynamics
Growing Shift toward Modern Oral Antidiabetic Therapies
The India diabetes care drugs market is experiencing a gradual transition toward modern oral antidiabetic medications that offer improved efficacy and patient convenience. Increased physician preference for newer drug classes is supported by their favorable safety profiles and suitability for long-term disease management. Expanding availability of cost-effective formulations is improving adoption across urban and semi-urban regions. Pharmaceutical companies are focusing on product differentiation and broader market reach to strengthen competitive positioning. This trend reflects an evolving treatment landscape aligned with patient-centric care. Demand for advanced oral therapies is expected to remain strong during the forecast period.
Expansion of Retail and Digital Pharmacy Channels
Distribution dynamics within the India diabetes care drugs market are evolving, driven by the expansion of retail and digital pharmacy networks. Retail pharmacies continue to serve as primary access points, especially in tier-2 and tier-3 cities. Online pharmacies are gaining momentum due to improved logistics, home delivery services, and digital prescription platforms. These channels are enhancing medication accessibility and continuity of care for chronic patients. Increased penetration of e-commerce and mobile health applications is supporting this trend. Distribution channel diversification is strengthening overall market reach and efficiency.
Market Segmentation
- Based on the diabetes type the market is segmented into type 1 diabetes, type 2 diabetes, gestational diabetes, and prediabetes.
- Based on the drug class the market is segmented into insulins, biguanides, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, and others.
- Based on the formulation & route the market is segmented into oral tablets, subcutaneous injections, and inhalable.
- Based on the by distribution channel the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies.
Type 2 Diabetes as the Largest Contributor to Market Growth
The Type 2 diabetes sub-segment represents the most significant share of the India diabetes care drugs market, reflecting the country’s high prevalence of lifestyle-related metabolic conditions. Urbanisation, changing dietary habits, and sedentary lifestyles contribute to an expanding patient base requiring long-term pharmacological management. Domestic and multinational pharmaceutical firms are intensifying treatment availability, with broad adoption of both traditional agents and modern therapies to meet diverse clinical needs. Treatment adherence initiatives and earlier diagnosis practices are strengthening uptake across major regions. Policy support aimed at improving healthcare access and affordability further underpins this segment’s expansion. As a result, Type 2 diabetes continues to anchor market demand and revenue generation
Rapid Expansion of SGLT2 Inhibitors as a Leading Drug Class
Among drug classes, SGLT2 inhibitors are emerging as one of the fastest-growing segments within India’s diabetes care drugs market, driven by increasing clinical recognition of their benefits in glycaemic control and associated cardiovascular and renal outcomes. Products such as empagliflozin and dapagliflozin are rapidly gaining traction, supported by a shift in prescribing patterns toward therapies with broader metabolic advantages and improved safety profiles. Leading global and Indian manufacturers are expanding their portfolios to capture this rising demand. Availability of more affordable versions and ongoing pipeline developments also encourage wider adoption across treatment settings. Recent entries by major players and growing generic competition highlight the segment’s dynamic growth trajectory.
Market Players Outlook
The major companies operating in the India diabetes care drugs market include AstraZeneca Pharma India Ltd., Biocon Ltd., Eli Lilly and Company, Novo Nordisk India Pvt. Ltd. and Sanofi India Ltd., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In December 2025, Cipla Ltd. announced the launch of Afrezza (insulin human) Inhalation Powder in India. Cipla had obtained regulatory approval from Central Drugs Standard Control Organisation (CDSCO) in 2024, for the exclusive distribution and marketing of Afrezza, a rapid-acting orally inhaled insulin, which offers a needle-free, convenient alternative to injectable insulin therapy.
- In December 2025, Novo Nordisk launched its GLP-1 drug Ozempic in India, available in 0.25 mg, 0.5 mg, and 1 mg pen doses. The launch targets India’s rapidly growing diabetes and obesity market, the second-largest globally after China. Ozempic, approved in the US in 2017, is also noted for reducing cardiovascular and kidney risks and is widely used off-label for weight loss.
- In October 2025, Biocon Biologics Ltd. announced expansion of its strategic collaboration with Civica, Inc. (Civica) to include a new Insulin Glargine medicine that will benefit patients in the India by increasing supply of affordable insulins. The multi-year transformational agreement between Biocon Biologics and Civica creates an exclusive distributorship arrangement where Biocon Biologics will manufacture and supply Insulin Glargine medicine to Civica, and Civica will commercialize under Biocon Biologics’ existing marketing approval.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the India diabetes care drugs Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- India Diabetes Care Drugs Market Sales Analysis – Diabetes Type | Drug Class | Formulation & Route | Distribution Channel | ($ Million)
- Diabetes Care Drugs Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Diabetes Care Drugs Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Diabetes Care Drugs Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For India Diabetes Care Drugs Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For India Diabetes Care Drugs Market: Impact Analysis
- Market Opportunities
- Opportunities For India Diabetes Care Drugs Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Diabetes Care Drugs Market Revenue and Share by Manufacturers
- Diabetes Care Drugs Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- AstraZeneca Pharma India Ltd
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Biocon Ltd
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Eli Lilly and Company
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Novo Nordisk India Pvt. Ltd.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Sanofi India Ltd.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- AstraZeneca Pharma India Ltd
- Key Company Analysis
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- India Diabetes Care Drug Market Sales Analysis by Diabetes Type ($ Million)
- Type 1 diabetes
- Type 2 diabetes
- Gestational diabetes
- Prediabetes
- India Diabetes Care Drug Market Sales Analysis by Drug Class ($ Million)
- Insulins
- Biguanides
- Sulfonylureas
- Thiazolidinediones (TZDs)
- DPP-4 inhibitors
- SGLT2 inhibitors
- Others
- India Diabetes Care Drug Market Sales Analysis by Formulation & Route ($ Million)
- Oral tablets
- Subcutaneous injections
- Inhalable
- India Diabetes Care Drug Market Sales Analysis by Distribution Channel ($ Million)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Company Profiles
- Alembic Pharmaceuticals Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Alkem Laboratories Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AstraZeneca Pharma India Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Aurobindo Pharma Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Biocon Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Cadila Healthcare Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Cipla Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Reddy’s Laboratories Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eli Lilly and Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GlaxoSmithKline Pharmaceuticals Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hetero Drugs Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Lupin Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Mankind Pharma Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Natco Pharma Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novo Nordisk India Pvt. Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi India Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sun Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Torrent Pharmaceuticals Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- USV Pvt. Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Zydus Lifesciences Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Alembic Pharmaceuticals Ltd.
1. India Diabetes Care Drug Market Research and Analysis by Diabetes Type, 2025–2035 ($ Million)
2. India Type 1 Diabetes Care Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
3. India Type 2 Diabetes Care Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
4. India Gestational Diabetes Care Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
5. India Prediabetes Care Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
6. India Diabetes Care Drug Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
7. India Insulin Market Research and Analysis by Region, 2025–2035 ($ Million)
8. India Biguanides Market Research and Analysis by Region, 2025–2035 ($ Million)
9. India Sulfonylureas Market Research and Analysis by Region, 2025–2035 ($ Million)
10. India Thiazolidinediones (TZDs) Market Research and Analysis by Region, 2025–2035 ($ Million)
11. India DPP-4 Inhibitors Market Research and Analysis by Region, 2025–2035 ($ Million)
12. India SGLT2 Inhibitors Market Research and Analysis by Region, 2025–2035 ($ Million)
13. India Other Diabetes Care Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
14. India Diabetes Care Drug Market Research and Analysis by Formulation & Route, 2025–2035 ($ Million)
15. India Oral Diabetes Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
16. India Subcutaneous Diabetes Injections Market Research and Analysis by Region, 2025–2035 ($ Million)
17. India Inhalable Diabetes Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
18. India Diabetes Care Drug Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
19. India Diabetes Care Drug Sale Via Hospital Pharmacies Market Research and Analysis by Region, 2025–2035 ($ Million)
20. India Diabetes Care Drug Sale Via Retail Pharmacies Market Research and Analysis by Region, 2025–2035 ($ Million)
21. India Diabetes Care Drug Sale Via Online Pharmacies Market Research and Analysis by Region, 2025–2035 ($ Million)
1. India Diabetes Care Drug Market Share by Type, 2025 Vs 2035 (%)
2. India Type 1 Diabetes Care Drug Market Share by Region, 2025 Vs 2035 (%)
3. India Type 2 Diabetes Care Drug Market Share by Region, 2025 Vs 2035 (%)
4. India Gestational diabetes Care Drug Market Share by Region, 2025 Vs 2035 (%)
5. India Prediabetes Care Drug Market Share by Region, 2025 Vs 2035 (%)
6. India Diabetes Care Drug Market Share by Service Provider, 2025 Vs 2035 (%)
7. India Insulins Market Share by Region, 2025 Vs 2035 (%)
8. India Biguanides Market Share by Region, 2025 Vs 2035 (%)
9. India Sulfonylureas Market Share by Region, 2025 Vs 2035 (%)
10. India Thiazolidinediones (TZDs) Market Share by Region, 2025 Vs 2035 (%)
11. India DPP-4 Inhibitors Market Share by Region, 2025 Vs 2035 (%)
12. India SGLT2 Inhibitors Market Share by Region, 2025 Vs 2035 (%)
13. India Others Diabetes Care Drug Market Share by Region, 2025 Vs 2035 (%)
14. India Diabetes Care Drug Market Share by Formulation & Route, 2025 Vs 2035 (%)
15. India Oral Diabetes Drug Market Share by Region, 2025 Vs 2035 (%)
16. India Subcutaneous Diabetes Injections Market Share by Region, 2025 Vs 2035 (%)
17. India Inhalable Diabetes Drug Market Share by Region, 2025 Vs 2035 (%)
18. India Diabetes Care Drug Market Share by Distribution Channel, 2025 Vs 2035 (%)
19. India Diabetes Care Drug Sale Via Hospital Pharmacies Market Share by Region, 2025 Vs 2035 (%)
20. India Diabetes Care Drug Sale Via Retail Pharmacies Market Share by Region, 2025 Vs 2035 (%)
21. India Diabetes Care Drug Sale Via Online Pharmacies Market Share by Region, 2025 Vs 2035 (%)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the India Diabetes Care Drugs Market in 2025 is estimated to be around $2,983.2 million.
Leading players in the India Diabetes Care Drugs Market include AstraZeneca Pharma India Ltd., Biocon Ltd., Eli Lilly and Company, Novo Nordisk India Pvt. Ltd. and Sanofi India Ltd., among others.
The India Diabetes Care Drugs Market is expected to grow at a CAGR of 9.0% from 2026 to 2035.
The India Diabetes Care Drugs Market growth is driven by the rising prevalence of diabetes and increasing awareness and access to advanced treatment options.
